

Postmarketing non-interventional safety study on medicinal products containing aromatase inhibitors, Anastrozol Actavis 1 mg, Exemestan Actavis 25 mg, Trozara 2,5 mg

First published: 02/11/2015

Last updated: 02/11/2015

Study

Planned

Administrative details

EU PAS number

EUPAS11481

Study ID

11482

DARWIN EU® study

No

Study countries

 Czechia

Study description

PASS searching and collecting reports on adverse drug reaction, possibility of follow-up of the development of the clinical status of a patient and analyze reports.

Study status

Planned

Research institutions and networks

Institutions

Actavis

First published: 01/02/2024

Last updated: 01/02/2024

Institution

Contact details

Study institution contact

Eugenia Prochazkova Eugenia.Prochazkova@actavis.com

Study contact

Eugenia.Prochazkova@actavis.com

Primary lead investigator

Martin Pytlik

Study timelines

Date when funding contract was signed

Planned: 14/04/2014

Study start date

Planned: 16/05/2014

Data analysis start date

Planned: 30/04/2017

Date of final study report

Planned: 28/02/2018

Sources of funding

- Pharmaceutical company and other private sector

More details on funding

Actavis

Regulatory

Was the study required by a regulatory body?

No

Methodological aspects

Study type

Study type:

Non-interventional study

Scope of the study:

Assessment of risk minimisation measure implementation or effectiveness

Other

If 'other', further details on the scope of the study

Patient's and treatment characteristics

Main study objective:

Obtaining information about safety of the drug and patient's characteristics.

Study Design

Non-interventional study design

Cohort

Study drug and medical condition

Anatomical Therapeutic Chemical (ATC) code

(L02BG) Aromatase inhibitors

Aromatase inhibitors

Population studied

Age groups

- Adults (18 to < 46 years)

- Adults (46 to < 65 years)
 - Adults (65 to < 75 years)
-

Estimated number of subjects

450

Study design details

Data analysis plan

Query investigation with statistical evaluation of results.

Data management

ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

Data sources

Data sources (types)

[Administrative healthcare records \(e.g., claims\)](#)

Use of a Common Data Model (CDM)

CDM mapping

No

Data quality specifications

Check conformance

Unknown

Check completeness

Unknown

Check stability

Unknown

Check logical consistency

Unknown

Data characterisation

Data characterisation conducted

No